1995 Results

People

  1. Kris
    Kris
  2. Motzer
    Motzer
  3. Scher
    Scher
  4. Saltz
    Saltz
  5. Schwartz
    Schwartz
  6. Hudis
    Hudis
  7. Kelsen
    Kelsen
  8. Rosen
    Rosen
  9. Marks
    Marks
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)
  7. Sloan Kettering Institute Faculty (227)
  8. Hematologic Malignancies, Division of (224)
  9. Genitourinary Oncology Service (203)
  10. Molecular Pharmacology and Chemistry Program Faculty (172)
  1. "antineoplastic agents"
Formats
  1. Journal Article (1901)
  2. Review (47)
  3. Conference Paper (23)
  4. Editorial (7)
  5. Research Letter (6)
  6. Guidelines (4)
  7. Book Section (3)
  8. Correspondence (2)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)

More Groups

People
  1. Mark Kris (77)
  2. Robert Motzer (70)
  3. Howard Scher (58)
  4. Gary Schwartz (52)
  5. Leonard Saltz (52)
  6. Ting-Chao Chou (50)

More People

Years
  1. 2025 (16)
  2. 2024 (65)
  3. 2023 (49)
  4. 2022 (49)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Clinical Cancer Research (114)
  2. Journal of Clinical Oncology (111)
  3. Cancer (70)
  4. Seminars in Oncology (51)
  5. New England Journal of Medicine (43)
  6. Cancer Research (40)

More Publications

Publishers
  1. Elsevier Inc. (240)
  2. American Association for Cancer Research (187)
  3. Springer (175)
  4. American Society of Clinical Oncology (129)
  5. Wiley Blackwell (112)
  6. Nature Publishing Group (92)

More Publishers

Results (1995)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • National Cancer Institute combination therapy platform trial with Molecular Analysis for Therapy Choice (ComboMATCH)
    Editorial

    Meric-Bernstam, F.; Ford, J. M.; O'Dwyer, P. J.; Shapiro, G. I.; McShane, L. M.; Freidlin, B.; O'Cearbhaill, R. E.; George, S.; Glade-Bender, J.; Lyman, G. H.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Shedding light on PARP inhibitor response through functional imaging
    Editorial

    Liu, Y. L.; Zamarin, D.
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas
    Journal Article

    Gounder, M. M.; Bauer, T. M.; Schwartz, G. K.; Weise, A. M.; LoRusso, P.; Kumar, P.; Tao, B.; Hong, Y.; Patel, P.; Lu, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
    Journal Article

    Postel-Vinay, S.; Lam, V. K.; Ros, W.; Bauer, T. M.; Hansen, A. R.; Cho, D. C.; Stephen Hodi, F.; Schellens, J. H. M.; Litton, J. K.; Aspeslagh, S.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Mechanistic and thermal characterization of acupuncture for chemotherapy-induced peripheral neuropathy as measured by quantitative sensory testing
    Journal Article

    Zhi, W. I.; Baser, R. E.; Talukder, D.; Mei, Y. Z.; Harte, S. E.; Bao, T.
    Breast Cancer Research and Treatment (2023)

    Fulltext@MSK | Save
  • Impact of baseline expectancy on outcome prediction of real and sham acupuncture for persistent chemotherapy-induced peripheral neuropathy pain in solid tumor survivors: A secondary analysis of a randomized clinical trial
    Journal Article

    Li, X.; Zhi, L.; Han, K. Y.; Li, S. Q.; Ahmad, K.; Seluzicki, C.; Wang, R.; Bao, T.
    Integrative Cancer Therapies (2023)

    Fulltext@MSK | Save
  • Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial
    Journal Article

    DiSilvestro, P.; Banerjee, S.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dermatologist awareness of scalp cooling for chemotherapy-induced alopecia
    Research Letter

    Yin, L.; Klein, E. J.; Svigos, K.; Novice, T.; Gutierrez, D.; Oratz, R.; Lacouture, M. E.; Powers, M.; Senna, M.; Shapiro, J.; more...
    Journal of the American Academy of Dermatology (2023)

    Fulltext@MSK | Save
  • Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
    Journal Article

    Mato, A. R.; Hess, L. M.; Chen, Y.; Abada, P. B.; Konig, H.; Pagel, J. M.; Walgren, R. A.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Immunotherapy with anti-G(D2) monoclonal antibody in infants with high-risk neuroblastoma
    Journal Article

    Kushner, B. H.; Modak, S.; Kramer, K.; Basu, E. M.; Iglesias-Cardenas, F.; Roberts, S. S.; Cheung, N. K. V.
    International Journal of Cancer (2023)

    Fulltext@MSK | Save